Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 3159-3176

  Hernanz, R ^a,b   Martinez Revelles S ^b,c   Palacios, R ^a,b   Martin A ^a,b   Cachofeiro, V ^d   Aguado, A ^b,c   Garcia Redondo L ^b,c   Barrus M T ^a   De Batista, P R ^a   Briones, A M ^b,c   Salaices, M ^b,c   Alonso, M J ^a,b  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; APOCYNIN; CATALASE; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; N(G) NITROARGININE METHYL ESTER; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; STRESS ACTIVATED PROTEIN KINASE 1; SUPEROXIDE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE; HISTOPATHOLOGY; HYPERTENSION; INTRACELLULAR SIGNALING; MALE; MOLECULAR PATHOLOGY; MOUSE; MYOGRAPHY; NONHUMAN; NOX 1 GENE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SYSTOLIC BLOOD PRESSURE; TLR4 GENE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ANIMAL; AORTA; BLOOD PRESSURE; C57BL MOUSE; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE CELL; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; HYPERTENSION; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 4; UP-REGULATION; VASCULAR REMODELING;

EID: 84930210250     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13117     Document Type: Article

References (50)

1. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Arribas SM, Hillier C, González C, McGrory S, Dominiczak AF, McGrath JC, (1997). Cellular aspects of vascular remodeling in hypertension revealed by confocal microscopy. Hypertension 30: 1455-1464.
5. de Batista PR, Palacios R, Martín A, Hernanz R, Médici CT, Silva MASC, et al. (2014). Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PlosOne 9: e104020.
6. Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, et al. (2012). Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci 122: 535-543.
7. Bomfim GF, Echem C, Martins CB, Costa TJ, Sartoretto SM, Dos Santos RA, et al. (2015). Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci 122: 1-7.
8. Briones AM, Touyz RM, (2010). Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12: 135-142.
9. Briones AM, González JM, Somoza B, Giraldo J, Daly CJ, Vila E, et al. (2003). Role of elastin in spontaneously hypertensive rat small mesenteric artery remodelling. J Physiol 552: 185-195.
10. Briones AM, Rodríguez-Criado N, Hernanz R, García-Redondo AB, Rodrigues-Díez RR, Alonso MJ, et al. (2009). Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 54: 142-149.
11. Briones AM, Arribas SM, Salaices M, (2010). Role of extracellular matrix in vascular remodelling of hypertension. Curr Opin Nephrol Hypertens 19: 187-194.
12. Carpenter S, O'Neill LA, (2009). Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 422: 1-10.
13. de Ciuceis C, Porteri E, Rizzoni D, Rizzardi N, Paiardi S, Boari GE, et al. (2007). Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertens 20: 846-852.
14. de Ciuceis C, Rossini C, La Boria E, Porteri E, Petroboni B, Gavazzi A, et al. (2014). Immune mechanisms in hypertension. High Blood Press Cardiovasc Prev 21: 227-234.
15. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ, (2010). Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 209: 314-320.
16. Drummond GR, Selemidis S, Griendling KK, Sobey CG, (2011). Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471.
17. Eissler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, et al. (2011). Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res 34: 551-558.
18. González-Ramos M, Calleros L, Lõpez-Ongil S, Raoch V, Griera M, Rodríguez-Puyol M, et al. (2013). HSP70 increases extracellular matrix production by human vascular smooth muscle through TGF-β1 up-regulation. Int J Biochem Cell Biol 45: 232-242.
19. Harrison DG, (2014). The immune system in hypertension. Trans Am Clin Climatol Assoc 125: 130-138.
20. Hernesniemi JA, Raitakari OT, Kähönen M, Juonala M, Hutri-Kähönen N, Marniemi J, et al. (2008). Toll-like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity. The cardiovascular risk in young Finns study. Atherosclerosis 198: 152-159.
21. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, et al. (2004). Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109: 393-398.
22. Ji Y, Liu J, Wang Z, Liu N, (2009). Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 23: 265-276.
23. Jialal I, Kaur H, Devaraj S, (2014). Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J Clin Endocrinol Metab 99: 39-48.
24. Kawai T, Akira S, (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Liang CF, Liu JT, Wang Y, Xu A, Vanhoutte PM, (2013). Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. Arterioscler Thromb Vasc Biol 33: 777-784.
27. Lv J, Jia R, Yang D, Zhu J, Ding G, (2009). Candesartan attenuates Angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun 380: 81-86.
28. Marketou ME, Kontaraki JE, Zacharis EA, Kochiadakis GE, Giaouzaki A, Chlouverakis G, et al. (2012). TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients: the effect of intensive blood pressure-lowering. J Clin Hypertens (Greenwich) 14: 330-335.
29. Martín A, Pérez-Girõn JV, Hernanz R, Palacios R, Briones AM, Fortuño A, et al. (2012). Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens 30: 315-326.
30. Martínez-Revelles S, Avendaño MS, García-Redondo AB, Alvarez Y, Aguado A, Pérez-Girõn JV, et al. (2013). Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51-65.
31. Mathiassen ON, Buus NH, Sihm I, Thybo NK, Mørn B, Schroeder AP, et al. (2007). Small artery structure is an independent predictor of cardiovascular events in essential hypertension. J Hypertens 25: 1021-1026.
32. McCarthy CG, Goulopoulou S, Wenceslau CF, Spitler K, Matsumoto T, Webb RC, (2014). Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol 306: H184-H196.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Mulvany MJ, (2008). Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med Biol Eng Comput 46: 461-467.
35. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E, (2008). Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 40: 180-196.
36. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
37. Pérez-Girõn JV, Palacios R, Martín A, Hernanz R, Aguado A, Martínez-Revelles S, et al. (2014). Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 306: H1582-H1593.
38. Ponticos M, Smith BD, (2014). Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res 28: 25-39.
39. Rizzoni D, Agabiti-Rosei E, (2012). Structural abnormalities of small resistance arteries in essential hypertension. Intern Emerg Med 7: 205-212.
40. Savoia C, Schiffrin EL, (2006). Inflammation in hypertension. Curr Opin Nephrol Hypertens 15: 152-158.
41. Schiffrin EL, (2014). Immune mechanisms in hypertension and vascular injury. Clin Sci 126: 267-274.
42. Sollinger D, Eiβler R, Lorenz S, Strand S, Chmielewski S, Aoqui C, et al. (2014). Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension. Cardiovasc Res 101: 464-472.
43. Tang PC, Qin L, Zielonka J, Zhou J, Matte-Martone C, Bergaya S, et al. (2008). MyD88-dependent, superoxide-initiated inflammation is necessary for flow-mediated inward remodeling of conduit arteries. J Exp Med 205: 3159-3171.
44. Touyz RM, (2005). Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 90: 449-455.
45. Tsan MF, Gao B, (2004). Endogenous ligands of Toll-like receptors. J Leukoc Biol 76: 514-519.
46. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL, (2004). Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 22: 535-542.
47. Virdis A, Duranti E, Taddei S, (2011). Oxidative stress and vascular damage in hypertension: role of angiotensin II. Int J Hypertens 2011: 916310.
48. Virdis A, Dell'Agnello U, Taddei S, (2014). Impact of inflammation on vascular disease in hypertension. Maturitas 78: 179-183.
49. Wolf G, Bohlender J, Bondeva T, Roger T, Thaiss F, Wenzel UO, (2006). Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol 17: 1585-1593.
50. Yuen CY, Wong SL, Lau CW, Tsang SY, Xu A, Zhu Z, et al. (2012). From skeleton to cytoskeleton: osteocalcin transforms vascular fibroblasts to myofibroblasts via angiotensin II and Toll-like receptor 4. Circ Res 111: e55-e66.